FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

gton, D.C. 20549	

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* HULME ALLISON				2. Issuer Name and Ticker or Trading Symbol Ventyx Biosciences, Inc. [VTYX]							lationship of ck all applica Director		g Perso	n(s) to Issue			
(Last) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 01/11/2023							Officer (below)	give title		Other (specification)	pecify		
C/O VENTYX BIOSCIENCES, INC. 662 ENCINITAS BLVD, SUITE 250					4. If Amendment, Date of Original Filed (Month/Day/Year) 01/12/2023						Line)	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
(Street) ENCINITAS CA 92024											Form filed by More than One Reporting Person						
(City)	(S	itate)	(Zip)	F	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a the affirmative defense conditions of Rule 10b5-1(c). See Instruction												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			. Transacti Pate Month/Day	Execution Date,		Date,	Code (Instr.			5. Amount Securities Beneficial Owned Fo Reported	Form (D) or ollowing (I) (In		Direct I Indirect E tr. 4)	7. Nature of ndirect Beneficial Ownership Instr. 4)			
							Code V	Amount	(A) or (D)	Price	Transactio				msu. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)				
Stock Option (right to buy)	\$34.16	01/11/2023		A		20,427 ⁽¹⁾		(2)	01/11/2033	Common Stock	20,427(1)	\$0.00	20,427	7 ⁽¹⁾	D		

Explanation of Responses:

- 1. The Form 4 filed on January 12, 2023, erroneously reported that reporting person received an option award for 12,880 shares on January 11, 2023. The correct option award amount is for 20,427 shares.
- 2. One-thirty sixth (1/36th) of the Shares subject to the option will be scheduled to vest each month following the grant date, in each case subject to the reporting person continuing to be a Service Provider (as defined in the Company's 2021 Equity Incentive Plan) through the applicable vesting date.

Remarks:

/s/ Christopher Krueger, as Attorney-in-Fact

04/26/2023

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.